A Pill to Treat Covid-19? The U.S. Is Betting on It.
Source: New York Times
The U.S. government will invest $3.2 billion to develop antiviral pills for Covid-19, the Department of Health and Human Services announced on Thursday. Such a treatment could keep people out of the hospital and potentially save many lives in the years to come, as the virus becomes a perennial threat despite the distribution of effective vaccines. A number of other viruses, including influenza, H.I.V. and hepatitis C, can be treated with a simple pill.
But despite more than a year of research, no such drug exists for the coronavirus. Operation Warp Speed, the Trump administrations program for accelerating Covid-19 research, invested far more money in the development of vaccines than of treatments, a gap that the new program will try to fill. The new influx of money will speed up the clinical trials of a few promising drug candidates. If all goes well, some of those pills might become available by the end of this year. The Antiviral Program for Pandemics will also support research on entirely new drugs not just for the coronavirus, but for viruses that could cause future pandemics.
Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and a key backer of the program, said he looked forward to a time when Covid-19 patients could pick up antiviral pills from a pharmacy as soon as they tested positive for the coronavirus or develop Covid-19 symptoms. I wake up in the morning, I dont feel very well, my sense of smell and taste go away, I get a sore throat, Dr. Fauci said in an interview. I call up my doctor and I say, I have Covid and I need a prescription.
Dr. Faucis support for research on antiviral pills stems from his own experience fighting AIDS three decades ago. In the 1990s, his institute conducted research that led to some of the first antiviral pills for H.I.V., protease inhibitors that block an essential virus protein and can keep the virus at bay for a lifetime. In the early 2000s, researchers found that an antiviral called sofosbuvir could cure hepatitis C close to 100 percent of the time. Tamiflu, an over-the-counter pill for influenza, can cut the time it takes to recover from an infection, and reduce the chances that a bout of the flu will land someone in the hospital.
Read more: https://www.nytimes.com/2021/06/17/health/covid-pill-antiviral.html
DonViejo
(60,536 posts)musette_sf
(10,202 posts)Not sure how that made its way past the writer and editors.
BumRushDaShow
(129,179 posts)I expect the COVID-19 pandemic probably helped to delay getting all the ducks in a row, with "i"s dotted and "t"s crossed...
PARIS July 23, 2019 Sanofi signed an agreement with Roche for the exclusive over-the-counter (OTC) rights to Tamiflu® for the prevention and treatment of influenza or flu in the US. Under the terms of the agreement, Sanofi will be responsible for leading FDA negotiations for the OTC switch and subsequent exclusive marketing, scientific engagement and distribution of Tamiflu OTC in the US. Tamiflu is currently sold in the US by Genentech, a member of the Roche Group, for prescription use.
This is a strategic and important transaction for us as we strive to continually bring innovations to the market, says Alan Main, Executive Vice President, Consumer Healthcare, Sanofi. The US market is the largest OTC market in the world and a successful switch of Tamiflu to OTC would support our global cough and cold strategy by expanding into flu with a sustainable point of difference in the market. Tamiflu will offer a significant public health benefit once switched by providing increased access to a safe and efficacious treatment for the prevention and treatment of flu. People would be able to either reduce their chances of getting the flu or, at the first signals, appropriately treat as early as possible during the crucial first 48 hours without having to wait for a doctors appointment.
Flu is a condition for which there is no effective OTC anti-viral treatment. Currently consumers are only able to treat flu symptoms with the available OTC products. Early treatment will help prevent unnecessary spread of the disease. According to the Centers for Disease Control and Prevention (CDC), over 31 million people in the US suffer from the flu in the US each year, but only about 7 million were treated with an effective product like Tamiflu in 2017.
Under the agreement, in addition to leading the FDA negotiations, Sanofi will be responsible for leading the clinical program and funding all studies needed to support the OTC switch in the US in consultation with leading experts in the field. Roche will continue to market Tamiflu in the rest of the world. Sanofi will retain the rights to first negotiations for switch rights in other selected markets.
https://www.sanofi.com/en/media-room/press-releases/2019/2019-07-23-07-00-00